Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor.

Slides:



Advertisements
Similar presentations
Caption N-terminal domain A/B domain: ligand-independent domain AF1: Activation Function 1 DBD: DNA Binding Domain LBD: Ligand Binding Domain: ligand-dependent.
Advertisements

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Robert H. Oakley, PhD, John A. Cidlowski, PhD 
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Gonadal Steroid Action
Schematic representation of main EGFR-TKIs resistance mechanisms.
The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Oestrogen and progesterone action on endometrium: a translational approach to understanding endometrial receptivity  Steven L. Young  Reproductive BioMedicine.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
PRISMA study flow diagram
Kaplan-Meier curves for overall survival (OS) probability.
Methods distribution among the three EQAs
YouFei Guan, M.D., Ph.D., Matthew D. Breyer  Kidney International 
Plot with best overall response and study duration.
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.
Comparison of the LL95%CI rule with PE rules with similar behaviour: %acceptance of maximal RB for power 80% and 90% over all trials, for LL95%CI ≤0.65 rule,
Clinical courses of patients.
Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention.
Illustration of common sites of pelvic relapse post-radical cystectomy in patients with ≥pT3 tumours, 9 18 stratified by margins status - (L) positive.
Synaptic Ménage à Trois
(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.
Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.
Molecular spectra of BTC
Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.
Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.
PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.
Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.
Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.
Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.
Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Graph showing.
Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)
(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).
Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).
Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.
Proportion of continuous, intermittent, and limited (
Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.
The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.
Immunochemical staining for HMBG3 in normal cervix, CIN III and invasive carcinomas and could show absent staining in normal cervix (A), absent to weak.
Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.
Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (
Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.
Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.
Heterogeneity in the natural history of triple negative breast cancer.
Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups. Dot plots comparing changes.
(A) Survival curves according to clinical response.
Total number of KRAS variants identified and discussed by the Genomics Review Board from all Sarah Cannon Molecular Diagnostics reports. Total number of.
Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.
Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.
Prescribers’ responses rating their level of comfort on a scale of 1–5
Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.
Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.
Presentation transcript:

Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. PRs exist as either A (97 kDa) or B (120 kDa) translated from the same gene by the use of alternate promoters. Each isoform contains a C-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) and at least two transcriptional activation function (AF) domains. AF1 and AF2 are located within the aminoterminal domain (ATD) and the LBD, respectively. PRB contains an additional AF (AF3) within the unique 164-amino acid B-upstream segment. Adapted from Lange;13 Hill KK, et al.14 Jacques Bonneterre et al. ESMO Open 2016;1:e000072 Copyright © European Society for Medical Oncology. All rights reserved.